Natco Pharma

Mylan wins patent battle over sclerosis drug Copaxone

26 Aug 2016

Natco gets USFDA approval for generic version of Roche’s influenza drug Tamiflu

06 Aug 2016

Natco, partner settle patent suit over Gilead’s Tamiflu

15 Dec 2015

Natco to sell generic hepatitis C drug at Rs710 per tablet

12 Mar 2015

Gilead's patent for hepatitis C drug Sofosbuvir rejected in India

16 Jan 2015

Natco Pharma opposes Indian patent for Gilead’s hepatitis drug

11 Apr 2014

Gilead, whose medicine has been hailed by doctors as a breakthrough in treating hepatitis, has come under fire over its product's $1,000 per pill price tag in the US

Delhi HC bars export of Natco's generic cancer drug on Bayer’s plea

27 Mar 2014

Bayer, in its petition, has pointed out that the generic drug being made under compulsory licence is for sale in India and, thus, cannot be exported

Bayer appeals against grant of ‘Nexavar’ licence to Natco

07 May 2012

Natco granted compulsory licence for Bayer's Nexavar

12 Mar 2012

The compulsory licence, the first of its kind to be granted in India, enables Natco to sell the drug at up to Rs8,880 for a pack of 120 tablets against Rs284,428 for Bayer's Nexavar